Open Clinical Trials
Englewood Hospital’s physician-investigators are currently recruiting research subjects for participation in several clinical trials across various departments.
Anesthesiology
REGAIN: A Randomized Controlled Trial of Regional versus General Anesthesia for Promoting Independence After Hip Fracture
Principal Investigator: Gregg Lobel, MD
Coordinator: Hana Badivuku
Phone: 201-894-3163
NCT #: 02057505
Englewood Health IRB #: E-15-637
More Information (clinicaltrials.gov)
Cardiology
PROTECTED TAVR: Stroke PROTECTion with SEntinel During Transcatheter Aortic Valve Replacement
Principal Investigator: Joseph De Gregorio, MD
Coordinator: Beatriz Sosa
Phone: 201-608-2663
NCT #: 04149535
Englewood Health IRB #: E-20-812
More Information (clinicaltrials.gov)
Gastroenterology
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease
Principal Investigator: Mark Sapienza, MD
Coordinator: Hana Badivuku
Phone: 201-894-3163
NCT #: 03467958
Englewood Health IRB #: E-18-757
More Information (clinicaltrials.gov)
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease
Principal Investigator: Mark Sapienza, MD
Coordinator: Hana Badivuku
Phone: 201-894-3163
NCT #: 03464097
Englewood Health IRB #: E-18-756
More Information (clinicaltrials.gov)
Induction Study #1: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease
Principal Investigator: Mark Sapienza, MD
Coordinator: Hana Badivuku
Phone: 201-894-3163
NCT #: 03440372
Englewood Health IRB #: E-18-755
More Information (clinicaltrials.gov)
Gastroenterology / C Diff
Fecal Microbiota Transplantation (FMT) for the Treatment of Recurrent or Refractory Clostridium Difficile Infection (CDI)
Principal Investigator: Marc Fiorillo, MD
Coordinator: Hana Badivuku
Phone: 201-894-3163
NCT #: 01942447
Englewood Health IRB #: E-13-507
More Information (clinicaltrials.gov)
Gynecology
A randomized controlled trial to evaluate the efficacy of acupuncture versus aromatherapy as treatments to lessen nausea and vomiting associated with Adriamycin and Cytoxan
Principal Investigator: Tracy Scheller, MD
Coordinator: Nathalia Clark
Phone: 201-894-3088
NCT #: 04116697
Englewood Health IRB #: E-19-773
More Information (clinicaltrials.gov)
NICU
A Pilot Study to Look at the Use of a Stabilizing (Weighted) Pacifier vs. the Use of a Traditional Non-Stabilizing (Weighted) Pacifier to Improve Infant Comfort, Caregiver Satisfaction, and Safety During Non-Nutritive Sucking
Principal Investigator: Mary De Ritter, MSN, RN, CNL
Coordinator: Nathalia Clark
Phone: 201-894-3088
NCT #: 04095702
Englewood Health IRB #: E-19-782
More Information (clinicaltrials.gov)
Oncology
TH-138: Phase II randomized trial of carboplatin + pemetrexed + bevacizumab, with or without atezolizumab in stage IV non-squamous NSCLC patients who harbor a sensitizing EGFR mutation or have never smoked
Principal Investigator: Meghan Kaumaya, MD
Coordinator: Audrey Ades
Phone: 201-894-3603
NCT #: 03786692
Englewood Health IRB #: E-20-808
More Information (clinicaltrials.gov)
EAZ171: Prospective validation trial of taxane therapy (docetaxel or weekly paclitaxel) and risk of chemotherapy-induced peripheral neuropathy in African American women
Principal Investigator: Jill Morrison, MD
Coordinator: Audrey Ades
Phone: 201-894-3603
NCT #: 04001829
Englewood Health IRB #: E-19-794
More Information (clinicaltrials.gov)
Oncology / Bladder Cancer
A phase II study of dose-dense gemcitabine plus cisplatin (ddGC) in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterios DNA damage response (DDR) gene alterations
Principal Investigator: Brian Kim, MD
Coordinator: Audrey Ades
Phone: 201-894-3603
NCT #: 03609216
Englewood Health IRB #: E-18-748
More Information (clinicaltrials.gov)
Oncology / Breast Cancer
A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Principal Investigator: David Dubin, MD
Coordinator: Audrey Ades
Phone: 201-894-3603
NCT #: 01901094
Englewood Health IRB #: E-18-749
More Information (clinicaltrials.gov)
A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Principal Investigator: Jill Morrison, MD
Coordinator: Audrey Ades
Phone: 201-894-3603
NCT #: 02750826
Englewood Health IRB #: E-16-663
More Information (clinicaltrials.gov)
B-51: Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
Principal Investigator: David Dubin, MD
Coordinator: Audrey Ades
Phone: 201-894-3603
NCT #: 01872975
Englewood Health IRB #: E-16-651
More Information (clinicaltrials.gov)
COMET: Comparison Of Operative To Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial
Principal Investigator: Steven Brower, MD
Coordinator: Audrey Ades
Phone: 201-894-3603
NCT #: 02926911
Englewood Health IRB #: E-17-710
More Information (clinicaltrials.gov)
Oncology / Colon Cancer
A021502: Randomized Trial of Standard Chemotherapy alone or combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer with Deficient DNA Mismatch (ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer)
Principal Investigator: Minaxi Jhawer, MD
Coordinator: Audrey Ades
Phone: 201-894-3603
NCT #: 02912559
Englewood Health IRB #: E-18-752
More Information (clinicaltrials.gov)
A021703: Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Principal Investigator: Minaxi Jhawer, MD
Coordinator: Audrey Ades
Phone: 201-894-3603
NCT #: 04094688
Englewood Health IRB #: E-19-792
More Information (clinicaltrials.gov)
Oncology / Colorectal Cancer
A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination with or without Atezolizumab or Atezolizumab Monotherapy in First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Principal Investigator: Minaxi Jhawer, MD
Coordinator: Audrey Ades
Phone: 201-894-3603
NCT #: 02997228
Englewood Health IRB #: E-18-753
More Information (clinicaltrials.gov)
Oncology / Gastric Cancer
IMIGASTRIC II: Prospective, observational, multicenter study on minimally invasive gastrectomy for gastric cancer: robotic, laparoscopic and open surgery compared on operative and follow-up outcomes
Principal Investigator: Steven Brower, MD
Coordinator: Rahul Kukreja
Phone: 201-894-3917
NCT #: 02751086
Englewood Health IRB #: E-16-673
More Information (clinicaltrials.gov)
Oncology / Neuroendocrine
A021602 Advanced Neuroendocrine Tumors: “A021602, Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors after Progression on Everolimus (CABINET)
Principal Investigator: Minaxi Jhawer, MD
Coordinator: Audrey Ades
Phone: 201-894-3603
NCT #: 03375320
Englewood Health IRB #: E-18-754
More Information (clinicaltrials.gov)
Oncology / Pancreatic Cancer
A Phase III Multi-Center Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas
Principal Investigator: Minaxi Jhawer, MD
Coordinator: Nathalia Clark
Phone: 201-894-3088
NCT #: 03504423
Englewood Health IRB #: E-19-781
More Information (clinicaltrials.gov)
Oncology / Renal Cancer
EA8143: A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Principal Investigator: Maz Ganat, MD
Coordinator: Audrey Ades
Phone: 201-894-3603
NCT #: 03055013
Englewood Health IRB #: E-19-784
More Information (clinicaltrials.gov)
Pulmonary
PUL-042-501: A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and progression to COVID-19 in Adults Exposed to SARS-CoV-2
Principal Investigator: Srikant Kondapaneni, MD
Coordinator: Nathalia Clark
Phone: 201-894-3088
NCT #: 04313023
Englewood Health IRB #: E-20-819
More Information (clinicaltrials.gov)
R10933-10987-COV-2066: A master protocol assessing the safety, tolerability, and efficacy of anti-spike (S) SARS-COV-2 monoclonal antibodies for the treatment of hospitalized patients with COVID-19
Principal Investigator: Srikant Kondapaneni, MD
Coordinator: Hana Badivuku
Phone: 201-894-3163
NCT #: 04426695
Englewood Health IRB #: E-20-827
More Information (clinicaltrials.gov)